Exploring Cannabis Use in ADHD Management: Findings from a 2023 Scoping Review

Introduction

Francisco et al. published a scoping review in The Journal of Psychiatric Research on November 25, 2022, analyzing existing literature on cannabis use in ADHD populations. This comprehensive review highlights potential benefits, risks, and the significant gaps in our understanding of cannabis as a therapeutic option for ADHD.

Key Points

  1. Study Scope and Purpose
    • This review synthesized research on cannabis and ADHD to determine its effects on symptoms like inattention, hyperactivity, and impulsivity.
    • It also examined risks such as dependency and neurocognitive impacts.
  2. Key Findings
    • Potential Benefits:
      • Some evidence suggests cannabis or cannabinoids (THC/CBD) may alleviate hyperactivity and impulsivity in certain patients.
    • Risks and Concerns:
      • Cannabis use is associated with cognitive deficits, dependency, and negative outcomes, especially in adolescents.
    • Mixed Evidence:
      • Outcomes appear highly individualized, with no consensus on therapeutic efficacy.
  3. Clinical Implications
    • The findings caution against using cannabis as a standard treatment for ADHD due to its variable effects and potential risks.
    • More research is needed to explore dose-specific effects, the role of individual differences, and long-term outcomes.
  4. Research Gaps
    • Few studies directly compare cannabis to established ADHD treatments.
    • Lack of data on non-psychoactive cannabinoids (e.g., CBD) in managing ADHD symptoms.

The VitalPoint For Providers

While patient interest in cannabis for ADHD is growing, this review highlights the need for evidence-based guidance. Encourage discussions about cannabis use with ADHD patients, emphasizing its potential risks and the lack of definitive support for its efficacy. Future studies should explore individualized cannabinoid-based therapies to better serve this population.

Further Reading:

Cannabis Provider Research
VitalPoint Technologies, Inc.

Disclaimer

None of the statements in this announcement or via any web sites linked herein have been evaluated by the FDA. Furthermore, none of the statements in this announcement or any web sites linked herein should be construed as dispensing medical advice or making claims regarding the cure of diseases. You should consult a licensed health care professional before starting any supplement, dietary, or exercise program, especially if you are pregnant or have any pre-existing injuries or medical conditions. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.

Scroll to Top